Tissue biomarker panel as a surrogate marker for squamous subtype of pancreatic cancer

Sumit Sahni; Elizabeth A Moon; Viive M Howell; Shreya Mehta; Nick Pavlakis; David Chan; Mahsa S Ahadi; Anthony J Gill; Jaswinder Samra; Anubhav Mittal

doi:10.1016/j.ejso.2020.02.001

Tissue biomarker panel as a surrogate marker for squamous subtype of pancreatic cancer

Eur J Surg Oncol. 2020 Aug;46(8):1539-1542. doi: 10.1016/j.ejso.2020.02.001. Epub 2020 Feb 6.

Authors

Affiliations

¹ Northern Clinical School, Faculty of Medicine and Health, University of Sydney, Australia; Kolling Institute of Medical Research, University of Sydney, Australia; Australian Pancreatic Centre, St Leonards, Sydney, Australia.
² Northern Clinical School, Faculty of Medicine and Health, University of Sydney, Australia; Kolling Institute of Medical Research, University of Sydney, Australia.
³ Northern Clinical School, Faculty of Medicine and Health, University of Sydney, Australia; Kolling Institute of Medical Research, University of Sydney, Australia; Northern Sydney Cancer Center, Royal North Shore Hospital, St Leonards, NSW, Australia; Northern Cancer Institute, St Leonards and Frenchs Forest, NSW, Australia.
⁴ Northern Clinical School, Faculty of Medicine and Health, University of Sydney, Australia; Kolling Institute of Medical Research, University of Sydney, Australia; Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research, Royal North Shore Hospital, St Leonards, NSW, 2065, Australia.
⁵ Northern Clinical School, Faculty of Medicine and Health, University of Sydney, Australia; Kolling Institute of Medical Research, University of Sydney, Australia; Australian Pancreatic Centre, St Leonards, Sydney, Australia; Upper GI Surgical Unit, Royal North Shore Hospital and North Shore Private Hospital, Australia.
⁶ Northern Clinical School, Faculty of Medicine and Health, University of Sydney, Australia; Kolling Institute of Medical Research, University of Sydney, Australia; Australian Pancreatic Centre, St Leonards, Sydney, Australia; Upper GI Surgical Unit, Royal North Shore Hospital and North Shore Private Hospital, Australia. Electronic address: anubhav.mittal@sydney.edu.au.

PMID: 32061458
DOI: 10.1016/j.ejso.2020.02.001

Abstract

Background: Pancreatic ductal adenocarcinoma (PDAC) has been recently classified into four subtypes based on the gene expression levels, with squamous subtype having worst prognostic outcomes. However, gene expression analysis for each individual patient is not clinically feasible due to very high associated cost. We previously reported that levels of three biomarkers (S100A4, Ca-125 and Mesothelin) can be used to classify PDAC patients based on their survival outcomes. This project aimed to determine if this novel biomarker panel can be used as a surrogate to identify squamous PDAC subtype.

Methods: Using the Nanostring gene expression platform, tumor tissue from 24 PDAC patients were analysed for our novel biomarkers and markers associated with four PDAC subtypes.

Results: Gene expression of our biomarker panel (S100A4, Ca-125 and Mesothelin) closely clustered together with markers for squamous PDAC subtype.

Conclusion: These results highlight the potential of our biomarkers to be utilized for identification of squamous PDAC subtype.

Keywords: Biomarkers; Gene expression analysis; Pancreatic ductal adenocarcinoma; Squamous subtype.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Biomarkers, Tumor / blood
CA-125 Antigen / blood*
Carcinoma, Pancreatic Ductal / blood
Carcinoma, Pancreatic Ductal / diagnosis*
Carcinoma, Squamous Cell / blood
Carcinoma, Squamous Cell / diagnosis*
Female
GPI-Linked Proteins / blood*
Humans
Immunohistochemistry
Male
Mesothelin
Pancreatic Neoplasms / blood
Pancreatic Neoplasms / diagnosis*
S100 Calcium-Binding Protein A4 / blood*

Substances

Biomarkers, Tumor
CA-125 Antigen
GPI-Linked Proteins
S100 Calcium-Binding Protein A4
S100A4 protein, human
Mesothelin